Regulation (EU) 2025/1222 – Harmonised

Article 1

Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union . It shall apply from 1 February 2027. However, suppliers may classify, label and package substances and mixtures in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation from the date of entry into force of this Regulation.

Supplementary provisions

ANNEXSupplementary provisions

ANNEX Part 3, Table 3, of Annex VI to Regulation (EC) No 1272/2008 is amended as follows: (1) the following entries are inserted following the consecutive order of the index numbers corresponding to each entry: Index No Chemical Name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATEs Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘607-776-00-5 2-ethylhexanoic acid, monoester with propane-1,2-diol 285-503-5 85114-00-7 Repr. 1B H360D GHS08 Dgr H360D’ ‘612-300-00-4 N -1-naphthylaniline; N -phenylnaphthalen-1-amine 201-983-0 90-30-2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 H302 H373 (blood system, liver) H317 GHS07 GHS08 Wng H302 H373 (blood system, liver) H317 oral: ATE = 1 200 mg/kg bw’ ‘026-005-00-8 tetrairon tris(pyrophosphate); ferric pyrophosphate 233-190-0 10058-44-3 Eye Irrit. 2 H319 GHS07 Wng H319’ ‘604-103-00-7 α,α’-propylenedinitrilodi- o -cresol 202-374-2 94-91-7 Repr. 1B H360FD GHS08 Dgr H360FD’ ‘008-004-00-4 ozone 233-069-2 10028-15-6 Ox. Gas 1 Carc. 2 Muta. 2 Acute Tox. 1 STOT SE 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H270 H351 H341 H330 H370 (nervous system, respiratory system, cardiovascular system) H372 (nervous system, respiratory system) H400 H410 GHS03 GHS08 GHS06 GHS09 Dgr H270 H351 H341 H330 H370 (nervous system, respiratory system, cardiovascular system) H372 (nervous system, respiratory system) H410 inhalation: ATE = 10 ppmV STOT SE 1; H370: C ≥ 0,002 % STOT SE 2; H371: 0,0005 % ≤ C < 0,002 % STOT RE 1; H372: C ≥ 0,05 % STOT RE 2; H373: 0,01 % ≤ C < 0,05 % M = 100 M = 1’ ‘007-031-00-9 dinitrogen oxide 233-032-0 10024-97-2 Repr. 1B STOT SE 3 STOT RE 1 Ozone 1 H360Df H336 H372 (nervous system) H420 GHS08 GHS07 Dgr H360Df H336 H372 (nervous system) H420’ ‘056-006-00-9 barium chromate 233-660-5 10294-40-3 Carc. 1B H350 GHS08 Dgr H350’ ‘650-060-00-2 Chrysanthemum cinerariaefolium , extract from open and mature flowers of Tanacetum cinerariifolium obtained with supercritical CO 2 289-699-3 89997-63-7 Acute Tox. 4 Acute Tox. 4 STOT SE 1 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H332 H302 H370 (nervous system) H373 (respiratory tract, inhalation) H317 H400 H410 GHS07 GHS08 Dgr H332 H302 H370 (nervous system) H373 (respiratory tract, inhalation) H317 H410 inhalation: ATE = 2,6 mg/L (dusts or mists) oral: ATE = 730 mg/kg bw M = 1 000 M = 100’ ‘650-059-00-7 Chrysanthemum cinerariaefolium , extract from open and mature flowers of Tanacetum cinerariifolium obtained with hydrocarbon solvents 289-699-3 89997-63-7 Acute Tox. 4 Acute Tox. 4 STOT SE 1 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H332 H302 H370 (nervous system) H373 (respiratory tract, inhalation) H317 H400 H410 GHS07 GHS08 Dgr H332 H302 H370 (nervous system) H373 (respiratory tract, inhalation) H317 H410 inhalation: ATE = 2,6 mg/L (dusts or mists) oral: ATE = 730 mg/kg bw M = 1 000 M = 100’ ‘607-777-00-0 barium bis[2-chloro-5-[(2-hydroxy-1-naphthyl)azo]toluene-4-sulphonate]; C.I. Pigment Red 53:1 225-935-3 5160-02-1 Carc. 2 H351 GHS08 Wng H351’ ‘608-070-00-X 2-bromo-2-(bromomethyl)pentanedinitrile; [DBDCB] 252-681-0 35691-65-7 Acute Tox. 2 Acute Tox. 4 STOT RE 2 Eye Dam. 1 Skin Sens. 1A Aquatic Chronic 2 H330 H302 H373 (thyroid, central nervous system) H318 H317 H411 GHS06 GHS08 GHS05 GHS09 Dgr H330 H302 H373 (thyroid, central nervous system) H318 H317 H411 inhalation: ATE = 0,27 mg/L (dusts or mists) oral: ATE = 500 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,001 %’ ‘607-779-00-1 9-octadecenoic acid (Z)-, sulfonated, potassium salts [1]; Reaction products of fatty acids, C18 (unsaturated) alkyl with sulfur trioxide, potassium salts [2]; 9(or 10)-sulphooctadecanoic acid, potassium salt [3] 271-843-1 [1]; - [2]; 267-966-5 [3] 68609-93-8 [1]; - [2]; 67968-63-2 [3] Repr. 1B H360D GHS08 Dgr H360D’ ‘613-352-00-0 bixlozone (ISO); 2-(2,4-dichlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one — 81777-95-9 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 M = 10’ ‘603-248-00-3 2,3-epoxypropyl isopropyl ether 223-672-9 4016-14-2 Repr. 1B H360F GHS08 Dgr H360F’ ‘607-778-00-6 tetrahydrofurfuryl methacrylate 219-529-5 2455-24-5 Repr. 1B Skin Sens. 1A H360Df H317 GHS08 GHS07 Dgr H360Df H317’ ‘015-209-00-2 trimethyl phosphate 208-144-8 512-56-1 Carc. 1B Muta. 1B Repr. 1B Acute Tox. 4 STOT RE 2 H350 H340 H360FD H302 H373 (nervous system) GHS08 GHS07 Dgr H350 H340 H360FD H302 H373 (nervous system) oral: ATE = 1 300 mg/kg bw’ ‘602-111-00-5 fluoroethylene 200-832-6 75-02-5 Carc. 1A Muta. 2 H350 H341 GHS08 Dgr H350 H341 D’ ‘602-112-00-0 2-bromo-3,3,3-trifluoroprop-1-ene — 1514-82-5 Repr. 1B STOT SE 3 STOT SE 3 H360FD H335 H336 GHS08 GHS07 Dgr H360FD H335 H336’ ‘613-353-00-6 2-methyl-2 H -isothiazol-3-one hydrochloride; 2-methyl-2,3-dihydro-1,2-thiazol-3-one hydrochloride 247-499-3 26172-54-3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Acute Aquatic 1 Acute Chronic 1 H330 H311 H301 H314 H318 H317 H400 H410 GHS06 GHS05 GHS09 Dgr H330 H311 H301 H314 H317 H410 EUH071 inhalation: ATE = 0,15 mg/L (dusts or mists) dermal: ATE = 320 mg/kg bw oral: ATE = 180 mg/kg bw Skin. Sens 1A; H317: C ≥ 0,0015 % M = 10 M = 1’ ‘603-249-00-9 2,3-epoxypropyl o-tolyl ether 218-645-3 2210-79-9 Skin Irrit. 2 Skin Sens. 1A Muta. 2 Aquatic Chronic 2 H315 H317 H341 H411 GHS07 GHS08 GHS09 Wng H315 H317 H341 H411 C’ ‘607-780-00-7 methyl oct-2-ynoate 203-836-6 111-12-6 Skin Sens. 1A H317 GHS07 Wng H317’ ‘612-301-00-X dinotefuran (ISO); ( RS )-1-methyl-2-nitro-3-(tetrahydro-3-furylmethyl)guanidine - 165252-70-0 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H302 H400 H410 GHS07 GHS09 Wng H302 H410 oral: ATE = 2 000 mg/kg bw M = 10 M = 10’ (2) the entries corresponding to index numbers 015-012-00-1, 601-027-00-6, 602-025-00-8, 607-231-00-1, 613-044-00-6, 613-045-00-1, 615-008-00-5, 616-145-00-3, 616-211-00-1, 616-212-00-7 are replaced by the following entries respectively: Index No Chemical Name EC No CAS No Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) Specific Conc. Limits, M-factors and ATEs Notes ‘601-027-00-6 2-phenylpropene; α-methylstyrene 202-705-0 98-83-9 Flam. Liq. 3 Carc. 2 STOT SE 3 Eye Irrit. 2 Skin Sens. 1B Aquatic Chronic 2 H226 H351 H335 H319 H317 H411 GHS02 GHS08 GHS07 GHS09 Wng H226 H351 H335 H319 H317 H411 STOT SE 3; H335: C ≥ 25 % D’ ‘616-145-00-3 pethoxamid (ISO); 2-chloro- N -(2-ethoxyethyl)- N -(2-methyl-1-phenylprop-1-enyl)acetamide - 106700-29-2 Acute Tox. 4 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H302 H317 H400 H410 GHS07 GHS09 Wng H302 H317 H410 oral: ATE = 980 mg/kg bw M = 100 M = 10’ ‘015-012-00-1 tetraphosphorus trisulphide; phosphorus sesquisulphid 215-245-0 1314-85-8 Flam. Sol. 1 Self-heat. 1 Acute Tox. 4* H228 H251 H302 GHS02 GHS07 Dgr H228 H251 H302 T’ ‘602-025-00-8 1,1-dichloroethylene; vinylidene chloride 200-864-0 75-35-4 Flam. Liq. 1 Carc. 1B Muta. 2 Acute Tox. 1 Acute Tox. 3 STOT RE 1 Aquatic Chronic 3 H224 H350 H341 H330 H301 H372 (respiratory tract, kidney, liver) H412 GHS02 GHS08 GHS06 Dgr H224 H350 H341 H330 H301 H372 (respiratory tract, kidney, liver) H412 inhalation: ATE = 0,5 mg/L (vapours) oral: ATE = 300 mg/kg bw D’ ‘615-008-00-5 3-isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate; isophorone di-isocyanate 223-861-6 4098-71-9 Acute Tox. 1 Skin Corr. 1 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1A Aquatic Chronic 2 H330 H314 H334 H317 H411 GHS06 GHS05 GHS08 GHS09 Dgr H330 H314 H318 H334 H317 H411 EUH071 inhalation: ATE = 0,03 mg/L (dusts or mists) Resp. Sens. 1; H334: C ≥ 0,5 % Skin Sens. 1A; H317: C ≥ 0,001 % 2’ ‘613-045-00-1 folpet (ISO); N -(trichloromethylthio)phthalimide 205-088-6 133-07-3 Carc. 2 Acute Tox. 2 STOT RE 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H351 H330 H372 (respiratory tract) H318 H317 H400 H410 GHS08 GHS06 GHS05 GHS09 Dgr H351 H330 H372 (respiratory tract) H318 H317 H410 EUH066 inhalation: ATE = 0,30 mg/L (dusts or mists) STOT RE 1: C ≥ 5 % STOT RE 2: 0,5 % ≤ C < 5 % Skin Sens. 1A; H317: C ≥ 0,001 % M = 10 M = 10’ ‘613-044-00-6 captan (ISO); 1,2,3,6-tetrahydro- N -(trichloromethylthio)phthalimide 205-087-0 133-06-2 Carc. 2 Repr. 2 Acute Tox. 2 STOT RE 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H351 H361f H330 H372 H318 H317 H400 H410 GHS08 GHS06 GHS05 GHS09 Dgr H351 H361f H330 H372 H318 H317 H410 inhalation: ATE = 0,22 mg/L (dusts or mists) Skin Sens. 1A; H317: C≥ 0,001 % M = 10 M = 10’ ‘607-231-00-1 clopyralid (ISO); 3,6-dichloropyridine-2-carboxylic acid 216-935-4 1702-17-6 Eye Dam. 1 Aquatic Chronic 1 H318 H410 GHS05 GHS09 Dgr H318 H410 EUH066 M = 10’ ‘616-211-00-1 proquinazid (ISO); 6-iodo-2-propoxy-3-propylquinazolin-4(3 H )-one — 189278-12-4 Carc. 2 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H372 (thyroid, liver) H400 H410 GHS08 GHS09 Dgr H351 H372 (thyroid, liver) H410 M = 1 M = 10’ ‘616-212-00-7 3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate 259-627-5 55406-53-6 Acute Tox. 2 Acute Tox. 4 STOT RE 1 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H330 H302 H372 (larynx) H318 H317 H400 H410 GHS06 GHS08 GHS05 GHS09 Dgr H330 H302 H372 (larynx) H318 H317 H410 inhalation: ATE = 0,17 mg/L (dusts or mists) M = 10 M = 10’

Commission Delegated Regulation (EU) 2025/1222 of 2 April 2025 amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council as regards the harmonised classification and labelling of certain substances

Article 1

Article 2

Supplementary provisions

ANNEXSupplementary provisions

What to look at next